Amgen, Inc. is looking to improve upon known mechanisms of action to build out its portfolio in cardiometabolic diseases beyond its LDL cholesterol-lowering biologic Repatha (evolocumab), such as with its lipoprotein(a)-lowering drug olpasiran, and full Phase II results released at the American Heart Association Scientific Sessions suggest it may be competitive with Novartis AG’s leading Lp(a) candidate pelacarsen.
The company used a 7 November analyst call after its presentations at the AHA annual meeting to discuss emerging data...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)